Illumina has appointed Mike Bouchard to be vice president of finance. Bouchard had the same title at Websense, and he also has been director of finance at Gateway, global finance manager at Rohm & Haas Company, and chief financial officer at SAL Limited.
Agendia has named Richard Bender to the position of vice president and chief medical officer.
Bender most recently served as vice president and chief medical officer at Spectrum Pharmaceuticals, an oncology drug development firm. He also worked as medical director for the oncology division of Quest Diagnostics, and spent nearly two decades at Kaiser Permanente where he helped to develop the company’s clinical oncology program.
AutoGenomics this week appointed Laurence Demers and Eric Kentor to its board of directors.
Demers is a former president of the American Association of Clinical Chemistry and the National Academy of Clinical Biochemistry. He currently holds the position of distinguished professor of pathology and medicine at the Milton S. Hershey Medical Center at Pennsylvania State University.
Kentor is a former senior vice president, general counsel, and corporate secretary of MiniMed. Prior to MiniMed, he was the vice president of legal services for Health Net from 1987 until 1994.
Febit Biotech this week announced the formation of a scientific advisory board. Febit’s SAB includes: Mark Chee, who will serve as chairman, a former scientist at Affymetrix, co-founder of Illumina, and CEO of Prognosys Biosciences; Karoly Nikolich, who will serve as vice chairman, the former executive director of the Neuroscience Institute of Stanford University; David Lockhart, chief scientific officer at Amicus Therapeutics; Mostafa Ronaghi, co-founder of Pyrosequencing, ParAllele Bioscience, and NextBio; and Jeffrey Trent, the president and scientific director of the Translational Genomics Research Institute.